The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
Hepatitis B and C (HBV/HCV) coinfected patients have a potential risk of hepatitis B reactivation (HBVr) after direct-acting antivirals (DAAs) treatment. The study intends to investigate the predictive role of HBV biomarkers in HBVr. Forty-six HBV/HCV coinfected patients receiving DAAs were enrolled...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/8/1812 |
| _version_ | 1797431659526619136 |
|---|---|
| author | Chih-Wei Tseng Wen-Chun Liu Ping-Hung Ko Yen-Chun Chen Kuo-Chih Tseng Ting-Tsung Chang |
| author_facet | Chih-Wei Tseng Wen-Chun Liu Ping-Hung Ko Yen-Chun Chen Kuo-Chih Tseng Ting-Tsung Chang |
| author_sort | Chih-Wei Tseng |
| collection | DOAJ |
| description | Hepatitis B and C (HBV/HCV) coinfected patients have a potential risk of hepatitis B reactivation (HBVr) after direct-acting antivirals (DAAs) treatment. The study intends to investigate the predictive role of HBV biomarkers in HBVr. Forty-six HBV/HCV coinfected patients receiving DAAs were enrolled. All patients completed treatment and follow-up to the 12th-week post-DAA treatment (P12). Blood samples were measured for HBV biomarkers, including hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg), and HBV pregenomic RNA (HBV pgRNA). The predictive factors for HBVr after DAA treatment were analyzed. Among 31 patients without nucleot(s)ide analogue (NA) treatment, seven (22.5%, 7/31) developed HBVr without hepatitis flare-up. Patients with HBVr had higher HBsAg titers than those without HBVr from baseline to P12 (<i>p</i> = 0.008, 0.009, 0.004, and 0.006 at baseline, week 4, end of treatment, and P12, respectively). The baseline HBsAg level was the only predictive factor associated with HBVr (HR, 2.303; 95% CI, 1.086–4.882; <i>p</i> = 0.030). In predicting HBVr, a baseline HBsAg titer > 20 IU/mL had a sensitivity, specificity, positive predictive value, and negative predictive value of 85.7%, 75.0%, 50%, and 94.7%, respectively. No patient had HBVr if the baseline HBsAg titer was <8 IU/mL. Serum HBcrAg and HBV pgRNA levels had no role in predicting HBVr. In conclusion, HBV/HCV coinfected patients are at risk of HBVr after DAA treatment. The baseline HBsAg level was the predictive factor associated with HBVr. Patients with a baseline HBsAg titer < 8 IU/mL can be considered as not having HBVr. |
| first_indexed | 2024-03-09T09:48:22Z |
| format | Article |
| id | doaj.art-efd2e8982f464bb9b459d03d1f849efe |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T09:48:22Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-efd2e8982f464bb9b459d03d1f849efe2023-12-02T00:27:03ZengMDPI AGViruses1999-49152022-08-01148181210.3390/v14081812The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected PatientsChih-Wei Tseng0Wen-Chun Liu1Ping-Hung Ko2Yen-Chun Chen3Kuo-Chih Tseng4Ting-Tsung Chang5Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, TaiwanDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan 70101, TaiwanDepartment of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, TaiwanDepartment of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, TaiwanDepartment of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, TaiwanDepartment of Internal Medicine, National Cheng Kung University Hospital, Tainan 70101, TaiwanHepatitis B and C (HBV/HCV) coinfected patients have a potential risk of hepatitis B reactivation (HBVr) after direct-acting antivirals (DAAs) treatment. The study intends to investigate the predictive role of HBV biomarkers in HBVr. Forty-six HBV/HCV coinfected patients receiving DAAs were enrolled. All patients completed treatment and follow-up to the 12th-week post-DAA treatment (P12). Blood samples were measured for HBV biomarkers, including hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg), and HBV pregenomic RNA (HBV pgRNA). The predictive factors for HBVr after DAA treatment were analyzed. Among 31 patients without nucleot(s)ide analogue (NA) treatment, seven (22.5%, 7/31) developed HBVr without hepatitis flare-up. Patients with HBVr had higher HBsAg titers than those without HBVr from baseline to P12 (<i>p</i> = 0.008, 0.009, 0.004, and 0.006 at baseline, week 4, end of treatment, and P12, respectively). The baseline HBsAg level was the only predictive factor associated with HBVr (HR, 2.303; 95% CI, 1.086–4.882; <i>p</i> = 0.030). In predicting HBVr, a baseline HBsAg titer > 20 IU/mL had a sensitivity, specificity, positive predictive value, and negative predictive value of 85.7%, 75.0%, 50%, and 94.7%, respectively. No patient had HBVr if the baseline HBsAg titer was <8 IU/mL. Serum HBcrAg and HBV pgRNA levels had no role in predicting HBVr. In conclusion, HBV/HCV coinfected patients are at risk of HBVr after DAA treatment. The baseline HBsAg level was the predictive factor associated with HBVr. Patients with a baseline HBsAg titer < 8 IU/mL can be considered as not having HBVr.https://www.mdpi.com/1999-4915/14/8/1812hepatitis B surface antigenhepatitis B core-related antigenHBV pregenomic RNAhepatitis CHBV/HCV coinfectiondirect-acting antiviral |
| spellingShingle | Chih-Wei Tseng Wen-Chun Liu Ping-Hung Ko Yen-Chun Chen Kuo-Chih Tseng Ting-Tsung Chang The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients Viruses hepatitis B surface antigen hepatitis B core-related antigen HBV pregenomic RNA hepatitis C HBV/HCV coinfection direct-acting antiviral |
| title | The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients |
| title_full | The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients |
| title_fullStr | The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients |
| title_full_unstemmed | The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients |
| title_short | The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients |
| title_sort | predictive role of hepatitis b biomarkers on hbv reactivation following direct acting antiviral therapy in hbv hcv coinfected patients |
| topic | hepatitis B surface antigen hepatitis B core-related antigen HBV pregenomic RNA hepatitis C HBV/HCV coinfection direct-acting antiviral |
| url | https://www.mdpi.com/1999-4915/14/8/1812 |
| work_keys_str_mv | AT chihweitseng thepredictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT wenchunliu thepredictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT pinghungko thepredictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT yenchunchen thepredictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT kuochihtseng thepredictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT tingtsungchang thepredictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT chihweitseng predictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT wenchunliu predictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT pinghungko predictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT yenchunchen predictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT kuochihtseng predictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients AT tingtsungchang predictiveroleofhepatitisbbiomarkersonhbvreactivationfollowingdirectactingantiviraltherapyinhbvhcvcoinfectedpatients |